Trial Profile
A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Abexinostat (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms RENAVIV
- Sponsors Xynomic Pharmaceuticals
- 22 Jan 2024 Planned End Date changed from 30 Jun 2023 to 30 Jun 2025.
- 22 Jan 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Dec 2024.
- 18 Aug 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.